C. R. Bard, Inc. (NYSE:BCR) Files An 8-K Entry into a Material Definitive Agreement

Item1.01

On November22, 2016, C. R. Bard, Inc. (the Company), JPMorgan
Chase Bank, N.A., as Administrative Agent, and certain other
banks and financial institutions entered into AmendmentNo. 4 (the
Amendment) to that certain Credit Agreement dated as of
October12,2011 (the Credit Agreement).

The Amendment extends the commitment termination date from
November23, 2020 until November22, 2021.

In the ordinary course of their respective businesses, one or
more of the lenders, or their affiliates, have or may have
various relationships with the Company and its subsidiaries
involving the provision of a variety of financial services for
which they received, or will receive, customary fees and
expenses.

About C. R. Bard, Inc. (NYSE:BCR)

C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. It operates through the manufacturing and sale of medical devices segment. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD), end-stage renal disease (ESRD) and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs.

C. R. Bard, Inc. (NYSE:BCR) Recent Trading Information

C. R. Bard, Inc. (NYSE:BCR) closed its last trading session down -5.68 at 209.35 with 396,044 shares trading hands.